• Cowen & Co. maintains a "Buy" rating for Johnson & Johnson (NYSE:JNJ), raising its price target from $222 to $250.
• Zacks Investment Research identifies JNJ as a potential medical stock to exceed earnings expectations, supported by its Earnings ESP tool.
• JNJ's market capitalization stands at approximately $529.8 billion, with a recent price increase to $219.90, indicating strong investor confidence and market performance.

Johnson & Johnson (NYSE:JNJ) is a leading player in the healthcare sector, known for its wide range of medical devices, pharmaceuticals, and consumer health products. On January 22, 2026, Cowen & Co. maintained its "Buy" rating for JNJ, with the stock trading at $219.68. Despite this, the action remains as "hold," indicating a cautious approach.

TD Cowen raised its price target for JNJ from $222 to $250, as highlighted by TheFly. This suggests optimism about the company's future performance. Supporting this, Zacks Investment Research identifies JNJ as a medical stock that could exceed earnings expectations. The Zacks Earnings ESP tool indicates potential earnings surprises, making it an attractive investment option.

Currently, JNJ is priced at $219.90, showing a $1.89 increase, or 0.87%. The stock's daily range is between $218.10 and $222.15, with the latter being its highest price in the past year. This reflects strong investor confidence and market performance.

JNJ's market capitalization is approximately $529.8 billion, indicating its significant presence in the healthcare industry. With a trading volume of 2,203,607 shares, the stock remains actively traded. Over the past year, JNJ's lowest price was $141.50, showcasing its growth trajectory.

Overall, JNJ's current market position and potential for earnings surprises make it a compelling choice for investors. The raised price target and maintained "Buy" rating further reinforce its attractiveness in the healthcare sector.